|Articles|January 18, 2023

2022 Best Tech

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

Teen sports supplements: What to recommend, use with caution, and avoid

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

FAQ: What's new in COVID-19, RSV, and flu guidance?

Disease severity, phenotype predict systemic treatment response in pediatric alopecia areata